Diffuse Large B-Cell Lymphoma (DLBCL) Pipeline Insight, 2025: Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis

Strategic Insights -

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, accounting for approximately 25% to 30% of all cases. It typically manifests as rapidly enlarging lymph nodes or masses, which may occur within or outside the lymphatic system. DLBCL originates from abnormal B-cell proliferation, often stemming from germinal center B cells. Its development can be influenced by genetic mutations, immune system deficiencies, and infections such as the Epstein-Barr virus.

The report "Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2025," by DelveInsight, provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the DLBCL pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for DLBCL treatment. Around 75+ products are under various phases of clinical development like late-stage (Phase III), mid-stage (Phase II), early-stage products (Phase I), and pre-clinical and discovery stage candidates.

Key Takeaways:

  • DelveInsight's DLBCL pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for DLBCL treatment.
  • Pfizer stands out with drug candidates that have reached the most advanced stage of development-Phase III clinical trials.
  • In April 2024, Rituxan (rituximab) was approved for the treatment of various blood cancers, autoimmune disorders, and inflammatory conditions.
  • In March 2024, Lantern Pharma began dosing two participants in a Phase Ia/Ib clinical trial for LP-284, an experimental drug for relapsed or refractory NHL.
  • In May 2023, Bristol Myers Squibb reported positive topline results from two studies: TRANSCEND FL, a global Phase 2, open-label, multicenter, single-arm trial of Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1, open-label, multicenter, single-arm study of Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL).
  • Over 70 key companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others are evaluating new drugs for DLBCL to improve the treatment landscape.

Statistics:

  • Approximately 70+ companies are working to develop 75+ pipeline therapies for DLBCL treatment.
  • Pfizer has drug candidates that have reached the most advanced stage of development-Phase III clinical trials.
  • Around 75+ products are under various phases of clinical development like late-stage (Phase III), mid-stage (Phase II), early-stage products (Phase I), and pre-clinical and discovery stage candidates.

Sources:

  • M2 PressWIRE - July 9, 2025
  • DelveInsight's "Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2025" report
  • DelveInsight's report on Diffuse Large B-Cell Lymphoma pipeline insights